Clinical trials
Completed Blepharitis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 6 |
| 2009 | 6 |
| 2010 | 3 |
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 6 |
| Tarsus Pharmaceuticals, Inc. | 3 |
| Federal University of São Paulo | 2 |
| Nicox Ophthalmics, Inc. | 2 |
| University of Texas Southwestern Medical Center | 2 |
| Alcon Research | 1 |
| Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona | 1 |
| Azienda Ospedaliero-Universitaria Careggi | 1 |
| Bausch & Lomb Incorporated | 1 |
| BioTissue Holdings, Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Blepharitis | 40 |
| Dry Eye Syndromes | 6 |
| Meibomian Gland Dysfunction | 6 |
| Conjunctivitis | 3 |
| Keratitis | 3 |
| Corneal Diseases | 2 |
| Meibomitis | 2 |
| Cataract | 1 |
| Dacryocystitis | 1 |
| Eye Infections | 1 |
Trials
Showing 51 to 40 of 40. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.